Climb Bio
CLYM
80 hedge funds and large institutions have $221M invested in Climb Bio in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 10 closing their positions.
170% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 10
40% more capital invested
Capital invested by funds: $157M → $221M (+$63.7M)
23% more funds holding
Funds holding: 65 → 80 (+15)
21.8% more ownership
Funds ownership: 45.79% → 67.6% (+22%)
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$8.82M |
| 2 |
Millennium Management
New York
|
+$5.65M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.95M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.71M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$4.82M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.79M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$3.46M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.96M |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$2.64M |
CLYM Hedge Fund Activity: Q1 2026 in Review
80 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q1 2026, worth a combined $221M — up 40% from $157M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CLYM positions and 10 closed out — a net gain of 17 holders — while 25 added to existing stakes and 23 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $8.82M. The largest seller was ADAR1 Capital Management, cutting an estimated $4.82M.
- 80 institutional investors held Climb Bio (CLYM) as of Q1 2026, up from 65 in Q4 2025.
- Funds reported $221M of Climb Bio stock for Q1 2026, up 40% quarter-over-quarter.
- 27 funds opened new Climb Bio positions in Q1 2026 and 10 closed out, a net change of +17 holders.
- The largest Climb Bio buyer in Q1 2026 was Braidwell, an estimated $8.82M added.
- The largest Climb Bio seller in Q1 2026 was ADAR1 Capital Management, an estimated $4.82M sold.
Based on aggregated 13F filings for Q1 2026.